Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr.Reddy's Laboratories Ltd    DRREDDY   INE089A01023

News SummaryMost relevantAll newsSector newsTweets

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

share with twitter share with LinkedIn share with facebook
share via e-mail
03/05/2013 | 10:15am CET

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at [email protected]/ +91-40-66834297
Saunak Savla at [email protected]/ +91-40-49002135
Milan Kalawadia (USA) at [email protected]/ +1 908-203-4931

S Rajan at [email protected]/ +91-40-49002445

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
12/13 DR REDDY LABORATORIES : . Reddy's gets USFDA nod for melphalan hyochloride
12/04 DR REDDY LABORATORIES : . Reddy's Announces Approval of Impoyz Cream, 0.025% Fir..
12/02 DR REDDY LABORATORIES : Reddys gets nod to restart exports to EU from Visakhapat..
12/02 DR REDDY LABORATORIES : .Reddy`s gets USFDA nod for Impoyz cream
12/02 DR REDDY LABORATORIES : Arm gets fda nod for drug
12/01 DR REDDY LABORATORIES : .Reddy's Miyapur unit gets USFDA EIR report
12/01 Indian ADRs end mixed; Tata Motors, ICICI Bank fall
12/01 DR REDDY LABORATORIES : . Reddy’s Announces Approval of Impoyz™ (clo..
12/01 DR REDDY LABORATORIES : Gets nod to restart exports to eu from vizag plant
11/30 DR REDDY LABORATORIES : Faces securities class action lawsuit in us
More news
News from SeekingAlpha
12/01 Dr. Reddy?s announces approval of Impoyz cream, 0.025% first-cycle NDA
11/29 HOLD ON TO NEKTAR THERAPEUTICS : There Is Much More Ammunition Left In Its Partn..
11/21 FDA issues guidance on development of generic abuse-deterrent opioids
11/21 Celgene up 2% after would-be generic competitor misses deadline to file for R..
11/14 Dr. Reddy's launches generic Clolar in U.S.
Financials ( INR)
Sales 2018 147 B
EBIT 2018 16 465 M
Net income 2018 12 918 M
Debt 2018 31 109 M
Yield 2018 0,82%
P/E ratio 2018 28,62
P/E ratio 2019 17,82
EV / Sales 2018 2,76x
EV / Sales 2019 2,35x
Capitalization 375 B
Duration : Period :
Dr.Reddy's Laboratories Lt Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Technical analysis trends DR.REDDY'S LABORATORIES LT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 41
Average target price 2 586  INR
Spread / Average Target 14%
EPS Revisions
Gunupati Venkateswara Prasad Co-Chairman, Chief Executive Officer & MD
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Abhijit Mukherjee Chief Operating Officer
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659